These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 19796269)

  • 21. An increase in CD3+CD4+CD25+ regulatory T cells after administration of umbilical cord-derived mesenchymal stem cells during sepsis.
    Chao YH; Wu HP; Wu KH; Tsai YG; Peng CT; Lin KC; Chao WR; Lee MS; Fu YC
    PLoS One; 2014; 9(10):e110338. PubMed ID: 25337817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human umbilical cord mesenchymal stem cells confer potent immunosuppressive effects in Sjögren's syndrome by inducing regulatory T cells.
    Liu Y; Li C; Wang S; Guo J; Guo J; Fu J; Ren L; An Y; He J; Li Z
    Mod Rheumatol; 2021 Jan; 31(1):186-196. PubMed ID: 31859545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunosuppressive properties of mesenchymal stem cells: advances and applications.
    De Miguel MP; Fuentes-Julián S; Blázquez-Martínez A; Pascual CY; Aller MA; Arias J; Arnalich-Montiel F
    Curr Mol Med; 2012 Jun; 12(5):574-91. PubMed ID: 22515979
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Therapeutic Effect of ICAM-1-Overexpressing Mesenchymal Stem Cells on Acute Graft-Versus-Host Disease.
    Tang B; Li X; Liu Y; Chen X; Li X; Chu Y; Zhu H; Liu W; Xu F; Zhou F; Zhang Y
    Cell Physiol Biochem; 2018; 46(6):2624-2635. PubMed ID: 29763906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Umbilical cord-derived mesenchymal stem cells reversed the suppressive deficiency of T regulatory cells from peripheral blood of patients with multiple sclerosis in a co-culture - a preliminary study.
    Yang H; Sun J; Wang F; Li Y; Bi J; Qu T
    Oncotarget; 2016 Nov; 7(45):72537-72545. PubMed ID: 27705922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mesenchymal stem cells enhance the induction of mixed chimerism and tolerance to rat hind-limb allografts after bone marrow transplantation.
    Pan H; Zhao K; Wang L; Zheng Y; Zhang G; Mai H; Han Y; Yang L; Guo S
    J Surg Res; 2010 May; 160(2):315-24. PubMed ID: 19524257
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults.
    Gonzalo-Daganzo R; Regidor C; Martín-Donaire T; Rico MA; Bautista G; Krsnik I; Forés R; Ojeda E; Sanjuán I; García-Marco JA; Navarro B; Gil S; Sánchez R; Panadero N; Gutiérrez Y; García-Berciano M; Pérez N; Millán I; Cabrera R; Fernández MN
    Cytotherapy; 2009; 11(3):278-88. PubMed ID: 19308773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro.
    Karlsson H; Erkers T; Nava S; Ruhm S; Westgren M; Ringdén O
    Clin Exp Immunol; 2012 Mar; 167(3):543-55. PubMed ID: 22288598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterogeneity in Studies of Mesenchymal Stromal Cells to Treat or Prevent Graft-versus-Host Disease: A Scoping Review of the Evidence.
    Rizk M; Monaghan M; Shorr R; Kekre N; Bredeson CN; Allan DS
    Biol Blood Marrow Transplant; 2016 Aug; 22(8):1416-1423. PubMed ID: 27130504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications.
    Baron F; Ruggeri A; Nagler A
    Expert Rev Hematol; 2016 Mar; 9(3):297-314. PubMed ID: 26635058
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recipient-Derived Allo-iTregs Induced by Donor DCs Effectively Inhibit the Proliferation of Donor T Cells and Reduce GVHD.
    Yang ZG; Wen RT; Feng JS; Cao PJ; Zhou HT; Liu WX
    Anat Rec (Hoboken); 2019 May; 302(5):825-836. PubMed ID: 30312018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can we prevent or treat graft-versus-host disease with cellular-therapy?
    Zahid MF; Lazarus HM; Ringdén O; Barrett JA; Gale RP; Hashmi SK
    Blood Rev; 2020 Sep; 43():100669. PubMed ID: 32089398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Role of bone marrow-derived mesenchymal stem cells in reduction of graft-versus-host disease by effecting CD4+CD25+ regulatory T cells in rats].
    Tian Y; Deng YB; Huang YJ; Na XD; Li Y; Ye MH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1210-4. PubMed ID: 17204196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation.
    Bejanyan N; Rogosheske J; DeFor TE; Lazaryan A; Arora M; Holtan SG; Jacobson PA; MacMillan ML; Verneris MR; Blazar BR; Weisdorf DJ; Wagner JE; Brunstein CG
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):2025-2030. PubMed ID: 27519278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bone marrow-derived conventional, but not cloned, mesenchymal stem cells suppress lymphocyte proliferation and prevent graft-versus-host disease in rats.
    Kitazawa Y; Li XK; Xie L; Zhu P; Kimura H; Takahara S
    Cell Transplant; 2012; 21(2-3):581-90. PubMed ID: 22793067
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
    Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
    Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The mixed human umbilical cord blood-derived mesenchymal stem cells show higher antitumor effect against C6 cells than the single in vitro.
    Jiao H; Yang B; Guan F; Li J; Shan H; Song L; Hu X; Liang S; Du Y; Jiang C
    Neurol Res; 2011 May; 33(4):405-14. PubMed ID: 21535940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tolerance to Bone Marrow Transplantation: Do Mesenchymal Stromal Cells Still Have a Future for Acute or Chronic GvHD?
    Introna M; Golay J
    Front Immunol; 2020; 11():609063. PubMed ID: 33362797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
    Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.